Xeris Biopharma Holdings, Inc. (XERS) Stock Price & Analysis

Xeris Biopharma Holdings, Inc. (XERS) closed at USD 10.75 on Thursday, October 29, 2026, up 1.03% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 10.64; the Oct 29, 2026 session ranged USD 10.71–10.94 on volume of 1,712,708 shares. Market capitalization is $1.96B, with a 52-week range of USD 5.25–11.42 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:11 UTC.

Also available as compact Markdown for AI agents: nexqual.com/XERS.md

Key facts (XERS)

• Last four reported quarters (through Jun 30, 2026): revenue $335M, net income -$17.2M (-5.1% margin) (SEC filings).
• Insider open-market sales, last ~7 months: 19 Form 4 filings, $3.0M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 12.86 (range 8–18).
• Total return with dividends: 1Y +10.7% vs S&P 500 +13.1%; 5Y +478.0% vs S&P 500 +79.1%.
• Next earnings: 2026-11-05, EPS estimate USD 0.03, revenue estimate $102M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (XERS)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (XERS)

P/S 5.8x · Earnings yield -0.88%

P/E at fiscal year-ends: Dec 2025 2447.7x.

Insider sales (SEC Form 4, open-market, last ~7 months) (XERS)

19 of 19 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (XERS)

Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 12.86 (low 8, high 18).

Rating changes, last 120 days:

Total return (dividends reinvested) (XERS)

XERS earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

XERS recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

XERS revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

XERS suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 2, 2026.

XERS company outlook (results filed Aug 6, 2026)

• “We received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new Keveyis patent expected to extend intellectual property protection through at least 2039, reinforcing our long-term commitment to the primary periodic paralysis community.”
• “Once granted, it is expected to provide intellectual property protection for Keveyis through at least 2039. • Notice of Allowance for New Patent Covering XP-8121: On July 28, 2026, the USPTO granted Xeris U.S.”

Quoted word-for-word from the SEC 8-K results press release.

XERS analyst estimates and revisions

XERS options: expected move

Options price a move of about ±25.9% (±$2.75) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±11.4% on average.

30-day implied volatility 78.9% vs 59% realized over the last 30 trading days. Put/call ratio (volume) 1.21. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:11 UTC)

Technical Analysis (XERS)

Nexqual's technical model rates XERS "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 20:11 UTC.

Analyst Ratings (XERS)

Wall Street analysts rate XERS "Buy" based on 7 analysts, with a mean price target of USD 12.86 (range USD 8–18), per Nexqual as of October 29, 2026 at 20:11 UTC.

Earnings (XERS)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:11 UTC.

Financials & Fundamentals (XERS)

Source: Nexqual, October 29, 2026 at 20:11 UTC.

Financial Health Score (XERS)

Nexqual rates Xeris Biopharma Holdings, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 20:11 UTC.

Ownership (XERS)

Source: Nexqual, October 29, 2026 at 20:11 UTC.

Leadership (XERS)

Xeris Biopharma Holdings, Inc. is led by John P. Shannon, Chairman & CEO, per Nexqual as of October 29, 2026 at 20:11 UTC.

Major Backers & Investors (XERS)

Notable institutional backers of Xeris Biopharma Holdings, Inc. include Shaw D.E. & Co., Inc., Rosalind Advisors, Inc., Qube Research & Technologies Ltd, according to Nexqual as of October 29, 2026 at 20:11 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:11 UTC.

From Xeris Biopharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• Included in the total patents, we have 69 granted patents globally related to our platform technologies, and 5 patents granted and in force in the United States and listed in the United States Food and Drug Administration ("FDA") Orange Book covering proprietary formulations of levoketoconazole (the active pharmaceutical ingredient in Recorlev) and the uses of such formulations in treating certain endocrine-related diseases and syndromes.
• We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
• We believe this therapy represents a significant commercial opportunity in the United States, with the potential to generate approximately $1 billion in annual net revenue at peak penetration. •Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia.
• The estimated total addressable market for this therapy is 3-5 million patients or more in the United States which we estimate is a $1.0 to $3.0 billion peak net sales opportunity. •Partnerships: We are pursuing formulation and development partnerships to apply our XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies' proprietary drugs and biologics.

Partnerships

• We have entered into a non-exclusive supply agreement with Bachem.
• We have entered into a non-exclusive supply agreement with Pyramid.

Legal & Regulatory Risks (Item 1A, quoted)

• We intend to utilize the 505(b)(2) pathway for the regulatory approval of certain of our product candidates. If the FDA does not conclude that such product candidates meet the requirements of Section 505(b)(2), final marketing approval of our product candidates by the FDA or other regulatory authorities may be delayed, limited, or denied, any of which would adversely affect our ability to generate operating revenues.
• Additional time may be required to obtain regulatory approval for certain of our product candidates because they are combination products.
• We have received orphan drug designation for Recorlev, Keveyis, and certain of our product candidates with respect to certain indications and may pursue such designation for others, but we may be unable to obtain such designation or to maintain the benefits associated with orphan drug status, including market exclusivity, even if that designation is granted.
• We may experience downward pricing pressure on the price of our products due to social or political pressure to lower the cost of drugs, which could reduce our revenue and future profitability.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:11 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt